55 results about "Schizophrenic disorders" patented technology

Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.

Provided are a histamine-H3 receptor antagonist; and a preventive and / or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute / congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit / hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

5- and 6-membered heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Also described is the treatment of neurological, neurodegenerative and psychiatric disorders including but not limited to those comprising cognitive deficits or schizophrenic symptoms.

The invention belongs to the field of psychiatry, nerve images and artificial intelligence, discloses a construction method of a first episode schizophrenia individualized prediction model, and solvesthe problem of low accuracy of auxiliary diagnosis of an existing SCH brain structure network model. The method comprises the following steps: A, acquiring a diffusion tensor image of a first episodeschizophrenia patient; B, preprocessing the obtained diffusion tensor image; C, constructing a sparse brain structure network based on the preprocessed image; D, constructing each sparse multi-threshold fusion brain structure network of the subject by adopting a similar network fusion method; E, extracting multi-threshold fusion brain structure network topology attribute features, and then carrying out feature screening; F, based on the screened features, adopting a classifier for classification training, and obtaining a first episode schizophrenia individualized prediction model is obtained;and G, performing performance verification and evaluation on the first episode schizophrenia individualized prediction model obtained by training.

One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

Disclosed is a medicinal composition for treating schizophrenosis which is prepared from plaster stone, rhubarb horsetails, baikal skullcap root, corktree bark, celestite, goldthread root, curcuma aromatica, mirabilite, keel, hooked uncaria, cow-bezoar, mirabilite, natural indigo, grassleaved sweetflag rhizome, mentha, magnolia bark, aloe, bamboo leaves, spatholobus stem, boneol, magnolia bark, aloe, Chinese angelica root, banksia rose, rough gentian, immature bitter orange, green tangerine orange peel and riddle.

Provided herein are methods for diagnosing a psychotic disorder, such as schizophrenia, schizoaffective disorder or psychosis, predicated on a determination of a methylation phenotype of the subject based in part on the identity of a specific polymorphism in the MTHFR gene and the analysis of a suite of biomarkers and other functional measures and indices. Also provided herein are methods for predicting prognosis and functional outcomes for subjects having a psychotic disorder, and for treating subjects having a psychotic disorder.

The present disclosure relates to compounds of formula (AI), (I), (AII), and (II), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, a pharmaceutical composition comprising a compound of formula (AI), (I), (AII), and (II), and use thereof, wherein R2, R3, R4, R5, R6, R7, R10, R11a, R11b, R12, R16, R19a, R19b, and R20 are described herein. Such compounds are envisioned useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, movement disorders, convulsive disorders, schizophrenin spectrum disorders, disorders of memory and / or cognition, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, or tinnitus etc.

Isoquinolone derivatives of the general formula I are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.

The invention relates to the field of pharmaceutical preparations, and in particular to an olanzapine orally disintegrating tablet for treating schizophrenia and psychosis with severe positive symptoms and / or negative symptoms and a preparation process thereof. The orally disintegrating tablet mainly comprises olanzapine, a filling agent, a disintegrating agent, a flavoring agent, a glidant, a lubricant and the like. Through regulating and controlling of components of the orally disintegrating tablet and a preparation process of the tablet, the defect of gravel feeling of the existing orally disintegrating tablet is eliminated. According to the preparation process provided by the invention, the layering phenomenon of medicines in a powder direct pressing preparation process is improved; and the prepared orally disintegrating tablet has the advantages of excellent mouthfeel, moderate sweetness, rapid disintegration, and good content uniformity, absorption and stability.

Deuterated forms of volinanserin according to structural formula (I), and their pharmaceutically acceptable salts, pharmaceutical compositions containing these compounds, and methods of treatment or prevention using these compounds or pharmaceutical compositions are described. The compounds are useful for treating or preventing a disease or condition selected from psychosis, schizophrenia, schizoaffective disorder, Parkinson's disease, Lewy body dementia, sleep disorder (including insomnia), agitation, mood disorder (including depression), thromboembolic disorder, autism, and attention deficit hyperactivity disorder.

The present disclosure relates to novel hydroxyl or halogen substituted derivatives of C11-C22 alkanoic acid ester of Paliperidone compound of formula (formula II) and process for preparing the same. The said compounds used in pharmaceutical composition for the treatment of schizophrenia and schizoaffective disorder, wherein, R═C10-C21 alkyl substituted by hydroxy or halogen.